INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $631,956 | -9.2% | 12,132 | +10.3% | 0.04% | -5.4% |
| Q2 2023 | $696,330 | +14.1% | 10,997 | -2.4% | 0.04% | -2.6% |
| Q1 2023 | $610,162 | +40.6% | 11,268 | +37.4% | 0.04% | +35.7% |
| Q4 2022 | $434,103 | +20.9% | 8,203 | +6.4% | 0.03% | +7.7% |
| Q3 2022 | $359,000 | -18.6% | 7,711 | -0.2% | 0.03% | -7.1% |
| Q2 2022 | $441,000 | -4.3% | 7,724 | +2.5% | 0.03% | +47.4% |
| Q1 2022 | $461,000 | +25.3% | 7,534 | +7.0% | 0.02% | +58.3% |
| Q4 2021 | $368,000 | +46.0% | 7,040 | +4.2% | 0.01% | +50.0% |
| Q3 2021 | $252,000 | -15.4% | 6,757 | -7.7% | 0.01% | -20.0% |
| Q2 2021 | $298,000 | +31.3% | 7,321 | +9.6% | 0.01% | +11.1% |
| Q1 2021 | $227,000 | +64.5% | 6,679 | -44.7% | 0.01% | 0.0% |
| Q4 2018 | $138,000 | -57.3% | 12,084 | -18.8% | 0.01% | -25.0% |
| Q3 2018 | $323,000 | – | 14,879 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |